These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, Chan JM, Anast JW, Carroll PR, Kane CJ. Urology; 2005 Nov; 66(5):1060-5. PubMed ID: 16286124 [Abstract] [Full Text] [Related]
3. Prostate brachytherapy: a descriptive analysis from CaPSURE. Lee WR, Sharkey J, Cowan JE, DuChane J, Carroll PR, CaPSURE Investigators. Brachytherapy; 2007 Nov; 6(2):123-8. PubMed ID: 17434105 [Abstract] [Full Text] [Related]
5. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. Culp S, Porter M. BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868 [Abstract] [Full Text] [Related]
6. The impact of obesity on overall and cancer specific survival in men with prostate cancer. Davies BJ, Smaldone MC, Sadetsky N, Dall'era M, Carroll PR. J Urol; 2009 Jul; 182(1):112-7; discussion 117. PubMed ID: 19447437 [Abstract] [Full Text] [Related]
7. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR. J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720 [Abstract] [Full Text] [Related]
8. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. Palma D, Pickles T, Tyldesley S, Prostate Cohort Outcomes Initiative. BJU Int; 2007 Aug; 100(2):315-9. PubMed ID: 17617138 [Abstract] [Full Text] [Related]
12. [Relationship between serum prostate-specific antigen levels and body mass index in Beijing men over 50 years of age]. Wang Y, Zhou Z, Tian Y, Shao Q, Chen S, Hong BF, Zhang XH, Ren XH, Sun WX, Wang ZW, Na YQ. Zhonghua Yi Xue Za Zhi; 2009 Jun 23; 89(24):1681-3. PubMed ID: 19957525 [Abstract] [Full Text] [Related]
14. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme. Pruthi RS, Swords K, Schultz H, Carson CC, Wallen EM. J Urol; 2009 Feb 23; 181(2):574-7; discussion 578. PubMed ID: 19084847 [Abstract] [Full Text] [Related]
15. Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE. Latini DM, Chan JM, Cowan JE, Arredondo SA, Kane CJ, Penson DF, DuChane J, Carroll PR, CaPSURE Investigators. Urology; 2006 Dec 23; 68(6):1242-7. PubMed ID: 17141841 [Abstract] [Full Text] [Related]
16. A better prognosis for obese men with prostate cancer. Daniell HW. J Urol; 1996 Jan 23; 155(1):220-5. PubMed ID: 7490839 [Abstract] [Full Text] [Related]
17. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators. Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313 [Abstract] [Full Text] [Related]